Nicoleta Andreescu, Maria Puiu, Adrian Vlad, Ioan Sporea, Alexandru Cătălin Motofelea, Iulia Teodora Perva, Iulia Elena Simina, Renata Bende, Adela Chirita Emandi, Alexandra Sima, Cristian Zimbru, Paul Calin Tutac, Mihai Dinu Niculescu
Journal: Medicina (Kaunas, Lithuania) 2024;60(8):
PMID: 39202647
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a common liver condition in individuals with obesity, linked to poor metabolism, fat build-up in the liver, and increased inflammation. Micronutrients (vitamins and minerals) play an essential role in supporting metabolic processes and protecting liver health. This study aimed to assess whether a micronutrient cocktail supplement could improve liver health and metabolic function in adults with obesity and MASLD. This research was a randomised, double-blind pilot clinical trial. Adults with obesity and MASLD were randomly assigned to receive either a micronutrient cocktail supplement, or a placebo, over a set intervention period. The results showed that participants who received the micronutrient cocktail had improved liver enzyme levels, indicating better liver function, reduced liver fat content, better blood sugar regulation and insulin sensitivity, and decreased markers of oxidative stress. The authors concluded that micronutrient supplementation may improve liver function and metabolic health in adults with MASLD and obesity. These findings are clinically relevant for healthcare practitioners because they suggest that targeted micronutrient therapy could serve as a supportive nutritional intervention in the management of MASLD, particularly when integrated with lifestyle changes.
: The goal of this study was to assess the impact of supplementation with a combination of nutrients on metabolic-dysfunction-associated steatotic liver disease (MASLD)-related liver parameters, and other parameters related to metabolic syndrome in adults with obesity. These measurements included anthropometric and lipid profiling, and FibroScan technology (controlled attenuation parameter (CAP) and transient elastography (TE) values). A double-blind, placebo-controlled pilot clinical trial was conducted over a three-month treatment period. Adults with metabolic syndrome and obesity were allocated to receive either a cocktail of nutrients with defined daily dosages (5-MTHF, betaine, alpha-linolenic acid, eicosapentaenoic acid, choline bitartrate, docosahexaenoic acid, and vitamin B12) or a placebo. The participants were evaluated at the start and the end of the three-month treatment period. : A total of 155 participants entered the study, comprising 84 in the treatment group and 71 in the placebo group. The administration of the nutritional supplement resulted in a notable reduction in both CAP and TE scores when compared to the placebo group. The treatment group exhibited a mean reduction in CAP of 4% ( < 0.05) and a mean reduction in TE of 7.8% ( < 0.05), indicative of a decline in liver fat content and fibrosis. : The supplementation over a period of three months led to a significant amelioration of liver fibrosis and steatosis parameters in adults with metabolic syndrome and obesity. These findings suggest that this supplementation regimen could be a beneficial adjunct therapy for improving liver health in adults with obesity-induced MASLD.
Full Text Sources:
Medical:
Miscellaneous:
© Copyright 2026, Nutrition Evidence
NED wishes to thank the following organisations for their support:
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.